

Psychedelics and Mental Health: A Population Study

Teri S. Krebs*, Pål-Ørjan Johansen

Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

Abstract

Background: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline.

Objective: To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population.

Method: Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events.

Results: 21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems.

Conclusion: We did not find use of psychedelics to be an independent risk factor for mental health problems.

Citation: Krebs TS, Johansen P-Ø (2013) Psychedelics and Mental Health: A Population Study. PLoS ONE 8(8): e63972. doi:10.1371/journal.pone.0063972

Editor: Lin Lu, Peking University, China

Received: August 19, 2012; **Accepted:** April 11, 2013; **Published:** August 19, 2013

Copyright: © 2013 Krebs, Johansen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Both authors were supported by the Research Council of Norway (grant 185924). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: krebs@ntnu.no

Introduction

Psychedelic plants have been used for celebratory, religious or healing purposes for thousands of years [1–3]. Use of psychedelics increased in the 1960s and has remained widespread in many parts of the world ever since. Over 30 million people living in the US have used lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline (peyote and other cacti) [4]. Common reasons for using psychedelics include mystical experiences, curiosity, and introspection [5]. The classical serotonergic psychedelics are not known to cause damage to the brain or other organs of the body, or cause withdrawal symptoms, elicit addiction or compulsive use [3], or cause birth defects or genetic damage [6]. Psychedelics often elicit deeply personally and spiritually meaningful experiences and sustained beneficial effects [7–12]. Psychedelics can often cause period of confusion and emotional turmoil during the immediate drug effects [13] and infrequently such adverse effects last for a few days after use. Psychedelics are not regarded to elicit violence [14] and dangerous behavior leading to suicide or accidental death under the influence of psychedelics is regarded as extremely rare [15]. LSD and

psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs [16–19]. Given that millions of doses of psychedelics have been consumed every year for over 40 years, well-documented case reports of long-term mental health problems following use of these substances are rare. Controlled studies have not suggested that use of psychedelics lead to long-term mental health problems [8,9,13,20]. Here we evaluate the association between the use of psychedelics and mental health among US adults.

Materials and Methods

Ethics Statement

This study was exempt from review by our Regional Committee for Medical Research Ethics because all data are available in the public domain without any identification of personal information. The National Survey on Drug Use and Health (NSDUH) was approved by an institutional review board of the Research Triangle Institute.

Source, Population and Data

The annual NSDUH survey provides estimates of substance use and mental health indicators from a randomly-selected sample representative of the general US civilian non-institutionalized adult population. The Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services is responsible for the NSDUH study design and methods of assessment. Trained interviewers met the randomly-selected participants in their homes, and participants listened to recorded questions via headphones and then entered their answers directly into a computer, providing a highly confidential and standardized setting. We pooled data from NSDUH survey years 2001 to 2004 because in these years participants were asked about symptoms of a range of psychiatric disorders and about whether they have been exposed to an extremely stressful event. We excluded half of the participants from year 2004 because of changes in the survey questions. We restricted the samples to adults aged 18 years and older because younger participants were asked different mental health questions than adults. The response rate was 78%. In addition, approximately 10% of participants were excluded from the public use data file, either because of excessive missing data on drug use or because they were excluded at random in order to increase anonymity. Detailed information on the sampling and data collection methods, including interview instructions and questionnaires, confidentiality and informed consent are available at the NSDUH website (<http://oas.samhsa.gov/nsduh.htm>).

Use of Psychedelics

We counted participants as having any lifetime psychedelic use if they affirmed use of LSD, psilocybin, mescaline, or peyote. We also examined use of each of the substances separately. Mescaline and peyote was combined into one category “mescaline/peyote” because mescaline is the active substance in peyote cactus, but peyote was also examined separately. Information was also available on past year use of LSD, but not past year use of psilocybin or mescaline. LSD, psilocybin, and mescaline are all classical serotonergic psychedelics with main mechanism of action at the serotonin 2A receptor [3,21].

Mental Health Indicators

Serious psychological distress. The K6 scale provides a valid assessment of general psychological distress during the worst month of the past year, that are common to a broad range of psychiatric disorders, with strong accuracy in discriminating between people with and without one or more diagnoses from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV [22]) [23]. The K6 scale asks about frequency, using a 0 to 4 category scale, of six symptoms of psychological distress: feeling nervous, feeling hopeless, feeling restless or fidgety, feeling so sad or depressed that nothing could cheer you up, feeling everything was an effort, and feeling no good or worthless. A score of 13 or more on the K6 scale is the validated and recommended cut-point for serious psychological distress [23].

Mental health treatment. Past year mental health treatment was divided into four outcome variables: inpatient mental health treatment, outpatient mental health treatment, psychiatric medication prescription, and felt a need but did not receive mental health treatment. Inpatient mental health treatment included overnight stays for alcohol or drug problems at hospitals or rehabilitation centers. Outpatient mental health treatment included treatment for alcohol or drug problems at rehabilitation centers, mental health centers, emergency rooms, doctors' offices, prisons or jails, or self-help groups. Data was not available on

medication prescription for alcohol or drug problems. Needed but did not receive mental health treatment included respondents who felt that they needed treatment for alcohol or drug problems but did not receive any such treatment.

Psychiatric symptom indicators. Symptoms indicators for eight DSM-IV psychiatric disorders were evaluated using the short form of the World Health Organization Composite International Diagnostic Interview (CIDI-SF) [23]. The CIDI-SF consists of between three to eight questions per disorder and covers eight disorders: panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis. We also examined each of the seven symptoms of non-affective psychosis individually (the cut-off for non-affective psychosis was two or more of the seven symptoms). The CIDI-SF appears to overestimate the rate of diagnoses, but most false-positive cases have some degree of the disorder even if they fail to meet full diagnostic criteria [23,24]. We used the CIDI-SF to compare groups on symptom indicators, not to estimate prevalence of psychiatric diagnoses. We used standard scoring and cut-off points [25].

Control Variables

We selected control variables based on associations with mental health in previous research [26]. Control variables consisted of a variety of sociodemographic, psychological, and drug use variables: age at interview (11 categories), gender, race/ethnicity (7 categories: non-Hispanic white, non-Hispanic black, non-Hispanic Native American, non-Hispanic Native Hawaiian or Pacific Islander, non-Hispanic Asian, non-Hispanic more than one race, Hispanic), education (4 categories: did not graduate high school; high school graduate; some college; college graduate), household income (4 categories: less than \$20,000; \$20,000 to \$49,999; \$50,000 to \$74,999; \$75,000 or more), marital status (2 categories: single; married), likes to test self with risky behavior (“How often do you like to test yourself by doing something a little risky?”; 4 categories: never, seldom, sometimes, always), lifetime exposure to an extremely stressful event (“Such as being in combat, being involved in a life-threatening accident, being involved in a disaster, being physically beaten or sexually abused, or any other event which was extremely upsetting or stressful”), and lifetime non-medical use of each of ten types of drugs: cannabis (marijuana), opiates (heroin, opiate pain relievers), cocaine, tranquilizers/sedatives (benzodiazepines, barbiturates), stimulants (amphetamine, methamphetamine, methylphenidate), MDMA (ecstasy), inhaled anesthetics (nitrous oxide, ether), alkyl nitrites (poppers), other inhalants (solvents, volatile chemicals), and PCP (phencyclidine). Additionally, in the analyses of past year use of LSD we also included as control variables past year use of the other drugs listed above, but with only one variable for any past year inhalant use because data on specific inhalants was not available.

Data Analysis

We used multivariate logistic regression to calculate associations between the past year mental health indicators and use of psychedelics, including lifetime use of any psychedelics, lifetime use of LSD, psilocybin, mescaline/peyote, or peyote, and past year use of LSD. We also calculated the associations between the past year mental health indicators and lifetime use of any psychedelics in the presence or absence of other risk factors in stratified subgroups (sex, age, past year illicit drug use, lifetime exposure to an extremely stressful event). Participants with missing data on relevant mental health outcomes or past year illicit drug use were excluded.

The estimated associations between the use of psychedelics are presented as adjusted odds ratios (aOR), 95% confidence intervals (CI), and *p*-values. A statistically significant odds ratio greater than one indicates an association, and an odds ratio less than one indicates an inverse association. Because the mental health outcomes are all relatively uncommon, in this case, the odds ratio is a close approximation to the relative risk. For example, an adjusted odds ratio of 0.6 for a given outcome indicates that the rate of that outcome in psychedelic users is approximately 60% the rate in non-psychedelic users, after adjusting for control variables.

We used a standard alpha of 0.05; however any significant results should be considered in the context of the number of statistical analysis performed. It is typically recommended to have at least 10 events per predictor variable for multivariate logistic regression, although recent simulation studies suggest as few as 5 events per predictor variable is sufficient [27]. All the unstratified analyses had at least 10 events per predictor variable, with 21 to 379 events per predictor variable for mental health indicators besides the specific psychotic symptoms. In the stratified analyses of three of the more uncommon specific psychotic symptoms (“force inserting thoughts”, “force stealing thoughts”, “plot to harm you”) there were in some cases less than 10 and as few as 5 events per predictor variable. For all control variables the variance inflation factors were under 2.5, indicating little multi-collinearity. All calculations took into account the weighting variables and complex sample design variables of the NSDUH. For all calculations we used SPSS/PASW Statistics (version 18.0.3) with the Complex Samples Module.

Results

Characteristics of Psychedelic Users

The sample consisted of 130,152 respondents, of which 21,979 (13.4% weighted) reported lifetime use of any psychedelic. Tables 1 and 2 show the characteristics of the participants, according to lifetime use of any psychedelic. Compared to respondents with no lifetime use of any psychedelic, respondents with lifetime use of any psychedelic were more likely to be younger, male, white, Native American, or more than one race, have somewhat higher income and more education, not be married, like to test self by doing risky things, experienced an extremely stressful event, and to have used all classes of illicit drugs. For all the control variables, the differences between psychedelic users and non-users was statistically significant (Chi-square tests, for all $p < 0.001$). Before adjusting for these confounding factors, psychedelic users had higher rates of all indicators of mental health problems.

Logistic Regression Results

Tables 3 and 4 show the results of the multivariate logistic regression analyzes.

Serious psychological distress. Lifetime psychedelic use was not significantly associated with serious psychological distress in the worst month of the past year. Among the specific psychedelics, lifetime psilocybin use (aOR 0.8, $p = 0.009$), lifetime mescaline use (aOR 0.9, $p = 0.04$), and past year LSD use (aOR 0.7, $p = 0.01$) were associated with lower rates of serious psychological distress.

Mental health treatment. Lifetime psychedelic use was not significantly associated with any of the mental health treatment variables. Among the specific psychedelics there were a number of significant associations with lower rate of receiving or needing mental health treatment. Lifetime LSD use was significantly associated with a lower rate of outpatient mental health treatment (aOR 0.9, $p = 0.002$) and psychiatric medication prescription

(aOR 0.9, $p = 0.04$). Lifetime psilocybin use was significantly associated with a lower rate of inpatient mental health treatment (aOR 0.8, $p = 0.04$) and psychiatric medication prescription (aOR 0.8, $p = 0.00008$). Lifetime mescaline/peyote use was significantly associated with a lower rate of psychiatric medication prescription (aOR 0.8, $p = 0.004$) and needed but did not receive mental health treatment (aOR 0.8, $p = 0.001$). Lifetime peyote use was significantly associated with a lower rate of psychiatric medication prescription (aOR 0.8, $p = 0.01$).

Psychiatric symptom indicators. Lifetime psychedelic use was not significantly associated with any of the eight past year psychiatric symptom indicators (aOR range 0.8 to 1.1), and lifetime psychedelic use was significantly associated with a lower rate of one of the seven psychotic symptoms (“Felt a force taking over your mind”: aOR 0.7, $p = 0.03$). Among the specific psychedelics, lifetime psilocybin use was significantly associated with a lower rate of symptoms of panic attacks (aOR 0.9, $p = 0.006$), and lifetime mescaline/peyote use was significantly associated with a lower rate of symptoms of agoraphobia (aOR 0.6, $p = 0.005$). Lifetime psilocybin use and lifetime mescaline/peyote use was significantly associated with a lower rate of one of the specific psychotic symptoms (“Felt a force taking over your mind”: psilocybin, aOR 0.6, $p = 0.004$; mescaline/peyote: aOR 0.7, $p = 0.04$).

Stratified samples. In a series of multivariate logistic regression analyzes stratified by gender (male; female), age (18 to 25 years; 26 and older), any past year illicit drug use (no; yes), or lifetime extremely stressful event ever (no; yes) there were no significant associations with lifetime psychedelic use and greater risk of any of the mental health outcomes. Rather, in twelve cases there was an association with psychedelic use and lower rate of various mental health outcomes; however, most of these cases had marginal statistical significance ($0.05 < p < 0.01$). Among females, psychedelic users had a lower rate of the psychotic symptom “felt force taking over mind” (aOR 0.5, 95% CI 0.3 to 0.7, $p = 0.0005$). Among younger people, psychedelic users had a lower rate of symptoms of generalized anxiety disorder (aOR 0.8, 95% CI 0.6 to 1.0, $p = 0.03$). Among older people, psychedelic users had a lower rate of psychiatric medications (aOR 0.9, 95% CI 0.8 to 1.0, $p = 0.03$) and the psychotic symptom “felt force taking over mind” (aOR 0.5, 95% CI 0.3 to 0.8, $p = 0.01$). Among people with past year illicit drug use, psychedelic users had a lower rate of inpatient mental health treatment (aOR 0.7, 95% CI 0.5 to 0.9, $p = 0.02$), needed mental health treatment (aOR 0.9, 95% CI 0.7 to 1.0, $p = 0.04$), symptoms of generalized anxiety disorder (aOR 0.7, 95% CI 0.5 to 1.0, $p = 0.05$), symptoms of agoraphobia (aOR 0.6, 95% CI 0.4 to 1.0, $p = 0.05$), and symptoms of posttraumatic stress disorder (aOR 0.7, 95% CI 0.5 to 1.0, $p = 0.02$). Among people without a lifetime extremely stressful event, psychedelic users had a lower rate of symptoms of psychosis (aOR 0.5, 95% CI 0.3 to 0.9, $p = 0.03$) and the psychotic symptoms “felt force inserting thoughts” (aOR 0.4, 95% CI 0.2 to 0.9, $p = 0.02$) and “felt force steal thoughts” (aOR 0.3, 95% CI 0.1 to 0.7, $p = 0.008$).

Native americans. Native Americans reported a high rate of lifetime psychedelic use (25%, weighted), with a high rate of lifetime peyote use (14%, weighted). However, less than 1% of lifetime psychedelic users and less than 3% of lifetime peyote users were Native Americans. Many Native Americans use peyote within legally-protected religious practice [24]. Excluding Native Americans changed the adjusted odds ratios on average less than 2%, and mescaline/peyote use was no longer statistically significantly associated with lower rate of the specific psychotic symptom “felt a force taking over your mind” (aOR = 0.7, $p = 0.06$).

Table 1. Characteristics of people who have used and not used psychedelics.

	Among used psychedelics		Among not used psychedelics		Used psychedelics, within each category
	wt %	N	wt %	N	wt %
Total	100%	21967	100%	108034	13.4%
Age					
18 to 25 years old	20.6%	11810	13.9%	51000	18.7%
26 years or older	79.4%	10157	86.1%	57034	12.5%
Sex					
Male	61.0%	12736	45.9%	48052	17.1%
Female	39.0%	9231	54.1%	59982	10.0%
Race/ethnicity					
White	85.7%	18399	69.5%	71732	16.0%
Hispanic	6.7%	1679	12.4%	14926	7.7%
Black	4.0%	621	12.2%	14331	4.8%
Asian	1.0%	250	4.3%	3843	3.4%
Native American	0.9%	399	0.4%	1060	25.2%
Native Hawaiian or Pacific Islander	0.2%	77	0.3%	492	9.6%
More than one	1.4%	542	0.9%	1650	20.0%
Household income					
Less than \$20,000	17.2%	5403	20.2%	27777	12.2%
\$20,000 to \$49,000	36.3%	8616	38.0%	42340	13.2%
\$50,000 to \$74,999	19.6%	3664	18.0%	17953	15.0%
\$75,000 or more	26.8%	4284	23.8%	19964	15.4%
Education					
Not high school graduate	13.2%	3727	18.0%	19174	10.2%
High school graduate	30.5%	7265	32.3%	36988	12.8%
Some college	29.7%	6757	24.3%	29775	15.9%
College graduate	26.6%	4217	25.4%	22056	14.0%
Marital status					
Not married	54.6%	14978	41.3%	62086	17.0%
Married	45.4%	6985	58.7%	45912	10.7%
Likes to test self by doing risky things					
Never	24.5%	4486	53.7%	48090	6.6%
Seldom	45.2%	9662	34.2%	40565	17.0%
Sometimes	27.3%	6780	11.1%	17174	27.6%
Always	3.1%	1017	1.1%	1922	31.1%
Extremely stressful event					
No	47.7%	10951	66.1%	71039	10.1%
Yes	52.3%	10938	33.9%	36361	19.3%
Lifetime use of other drugs					
Cannabis	98.2%	21542	33.0%	42705	31.5%
Opiates	46.2%	11249	7.7%	10958	48.1%
Cocaine	70.1%	14014	6.7%	6959	61.8%
Tranquilizers and sedatives	44.1%	8863	4.7%	5131	59.2%
Stimulants	41.8%	8648	3.7%	4455	63.3%
MDMA	24.7%	8074	1.2%	2680	75.9%
Inhaled anesthetics	28.5%	7515	1.6%	2735	74.0%
Alkyl nitrites	19.8%	3448	1.3%	1283	70.3%
Other inhalants	12.8%	2999	1.6%	2750	55.6%
PCP	21.0%	3752	0.4%	481	89.3%

Wt %, weighted percentage.
doi:10.1371/journal.pone.0063972.t001

Table 2. Drug use in psychedelic users and non-users.

	Among used psychedelics		Among not used psychedelics		Used psychedelics, within each category
	wt %	N	wt %	N	wt %
Total	100%	21967	100%	108034	13.4%
Psychedelics					
LSD	80.1%	17486	0%	0	100%
Psilocybin	61.5%	14413	0%	0	100%
Mescaline/peyote	37.8%	6254	0%	0	100%
Peyote	19.6%	3120	0%	0	100%
LSD past year		1220		0	100%
Lifetime use of other drugs					
Cannabis	98.2%	21542	33.0%	42705	31.5%
Opiates	46.2%	11249	7.7%	10958	48.1%
Cocaine	70.1%	14014	6.7%	6959	61.8%
Tranquilizers and sedatives	44.1%	8863	4.7%	5131	59.2%
Stimulants	41.8%	8648	3.7%	4455	63.3%
MDMA	24.7%	8074	1.2%	2680	75.9%
Inhaled anesthetics	28.5%	7515	1.6%	2735	74.0%
Alkyl nitrites	19.8%	3448	1.3%	1283	70.3%
Other inhalants	12.8%	2999	1.6%	2750	55.6%
PCP	21.0%	3752	0.4%	481	89.3%

Wt %, weighted percentage.
doi:10.1371/journal.pone.0063972.t002

Missing data. On each analysis, less than 2% of participants were missing data. Including participants with missing data by setting missing data to “no” or “0” had a minimal effect on the results (less than 4% change in adjusted odds ratios, on average) and had no effect on statistical significance.

Discussion

Lack of Associations with Mental Health Problems

We found no relation between lifetime use of psychedelics and any undesirable past year mental health outcomes, including serious psychological distress, mental health treatment (inpatient, outpatient, medication, felt a need but did not receive), or symptoms of panic disorder, major depressive episode, mania, social phobia, generalized anxiety disorder, agoraphobia, post-traumatic stress disorder, or non-affective psychosis. In addition to not being significantly different from no association, in all cases the calculated adjusted odds ratios (aOR) were small (for all, psychedelic use aOR ≤1.2). Stratifying by age, gender, past year illicit drug use, or lifetime extremely stressful event did not substantially change the results of any of the logistic regression analyses. Likewise, lifetime use of LSD, psilocybin, mescaline, or peyote, or past year use of LSD, was not associated with a higher rate of mental health problems. There were a number of weak associations between use of any psychedelic or use of specific psychedelics and lower rate of mental health problems; these results might reflect beneficial effects of psychedelic use, relatively better initial mental health among people who use psychedelics, or chance “false positive” findings. Our results are consistent with assessments of the harm potential of psychedelics [28,29] and with information provided by UN, EU, US, and UK official drug education programs [15,30–34], insofar as these sources do not

conclude that psychedelics are demonstrated to cause lasting anxiety, depression, or psychosis.

Limitations

This study had a retrospective, cross-sectional design, making it impossible to draw causal inferences. Many potentially important risk factors, such as family mental health history, were not available. Longitudinal data were not available on mental health or other factors before psychedelic use. We cannot exclude the possibility that use of psychedelics might have a negative effect on mental health for some individuals or groups, perhaps counter-balanced at a population level by a positive effect on mental health in others. We did not adjust for multiple comparisons, so some of the associations with weak statistical significance are likely due to chance. Screening questions, rather than diagnostic interviews, were used as symptom indicators. Self-reports of drug use behaviors and mental health questions could be influenced by memory errors and under-reporting; however, a 14-year longitudinal study reported good consistency over time in reporting of LSD use [35]. Dosage and purity of street drugs is often unknown, and in particular substances sold as mescaline often contain LSD or other substances [36]. A small group (<2%) of US adults in prison, hospital, or military service were not included in the NSDUH sampling. We did not examine active drug or short-term effects.

Clinical Studies in Healthy Volunteers

The lack of association between the use of psychedelics and indicators of mental health problems in this large population survey is consistent with clinical studies in which LSD or other psychedelics have been administered to healthy volunteers [13]. Eight recent double-blind, placebo-controlled studies of psilocybin

Table 3. Association between psychedelic use and mental health.

	Ever used psychedelics		Never used psychedelics		Adjusted OR ^a (95% CI)	p
	wt %	N	wt %	N		
Serious psychological distress in worst month of past year						
K6-scale	15.5%	3826	7.5%	10389	1.0 (0.9–1.1)	0.72
Mental health treatment in past year						
Inpatient	2.9%	708	0.9%	1135	0.9 (0.7–1.2)	0.53
Outpatient	15.2%	3343	6.5%	7739	0.9 (0.8–1.0)	0.13
Medication	16.3%	3320	9.1%	9135	0.9 (0.8–1.0)	0.05
Needed but did not receive	11.9%	2979	4.2%	6320	0.9 (0.8–1.1)	0.31
Symptoms of mental disorders in past year						
Panic disorder	16.5%	4018	8.5%	10867	1.0 (0.9–1.1)	0.62
Major depressive episode	6.8%	1640	2.7%	3828	1.0 (0.8–1.2)	0.80
Mania	1.9%	407	0.7%	717	1.1 (0.8–1.6)	0.53
Social phobia	1.4%	302	0.6%	690	0.9 (0.7–1.3)	0.76
Generalized anxiety disorder	3.2%	739	1.4%	1770	0.9 (0.7–1.1)	0.31
Agoraphobia	1.4%	320	0.7%	853	1.0 (0.6–1.6)	0.90
Posttraumatic stress disorder	3.2%	649	1.2%	1456	1.0 (0.8–1.3)	0.86
Non-affective psychosis ^b	4.4%	658	1.8%	1451	0.8 (0.6–1.1)	0.21
Specific psychotic symptoms in past year						
Heard voices others could not	4.3%	639	2.1%	1628	1.0 (0.8–1.4)	0.82
Felt force taking over mind	2.3%	324	0.9%	736	0.7 (0.5–1.0)	0.03
Felt force inserting thoughts	1.0%	159	0.5%	328	0.7 (0.5–1.2)	0.23
Felt force steal thoughts	1.3%	230	0.7%	547	0.7 (0.5–1.2)	0.21
Force used special signals	3.3%	508	1.3%	1195	0.9 (0.7–1.2)	0.50
Believed plot to harm you	2.1%	332	0.9%	732	0.8 (0.5–1.2)	0.22
Saw vision others could not	4.0%	604	1.8%	1525	1.0 (0.7–1.3)	0.77

^aAdjusted for age, gender, race/ethnicity, income, education, married, risky behavior, extremely stressful event, and ten types of lifetime drug use (cannabis/marijuana, opiates, cocaine, sedatives/tranquilizers, stimulants, MDMA/ecstasy, inhaled anesthetics, amyl nitrates, other inhalants, PCP).

^bData on symptoms of non-affective psychosis available only for years 2001–2002.

Bold indicates p<0.05.

doi:10.1371/journal.pone.0063972.t003

in healthy volunteers, with follow-up between 8 and 16 months, reported “no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long term impairment of functioning” [20]. And two other recent clinical trials of psilocybin in 54 healthy volunteers found no evidence of lasting adverse effects [8,9].

Cross-sectional and Case-control Studies

A case-control study of Native Americans failed to find any evidence of cognitive or mental health deficits among people who regularly used peyote in religious services compared to those who did not use peyote, rather total lifetime peyote use (mean 300 occasions, range 150–500) was associated with overall better mental health [37]. Likewise, a longitudinal case-control study found that people who had each used the shamanic beverage ayahuasca, containing the psychedelic dimethyltryptamine (DMT) which is chemically similar to psilocybin, in over 360 religious ceremonies scored significantly lower on all psychopathology measures compared to people who regularly participated in non-psychedelic religious groups, both at baseline and at one year follow-up [38]. A population study reported that any lifetime use of cocaine and/or psychedelics was associated with prior lifetime history of two or more of 15 psychotic symptoms, but not one

psychotic symptom [39]; in this study cocaine and amphetamine use were not included as control variables in the analyzes of psychedelic use, although both cocaine and amphetamine use were reported to be associated with psychotic symptoms; although the data came from a 10-year longitudinal study, data were aggregated over all time periods and no distinction was made between psychotic symptoms occurring before or after onset of psychedelic use. Another retrospective population study did not find an association between any lifetime “psychedelic” use and panic attacks or depression, but did report an association between dependence on “psychedelics” and panic attacks [40]; however, in this study the number of events was small, and the dissociative anesthetic PCP was included as a psychedelic, even though it is well known that PCP has quite different subjective effects, dependence potential, and neurobiological mechanisms than the serotonergic psychedelics. A follow-up of 29 patients with first-break psychosis attributed to LSD use found that these individuals were “essentially similar” to first-break psychosis patients with no LSD use in terms of premorbid adjustment, course of illness, and family history of inpatient treatment, and course of illness [41] (see also [28]).

Table 4. Association between use of LSD, psilocybin, mescaline, and peyote and mental health.

	Lifetime use				Past year use					
	LSD		Psilocybin		Mescaline/peyote		Peyote		LSD	
	Adjusted OR ^a (95% CI)	p	Adjusted OR ^a (95% CI)	p	Adjusted OR ^a (95% CI)	p	Adjusted OR ^a (95% CI)	p	Adjusted OR ^b (95% CI)	
Serious psychological distress in worst month of past year										
K6-scale	1.0 (0.9–1.1)	0.65	0.8 (0.7–1.0)	0.009	0.9 (0.8–1.0)	0.04	0.9 (0.7–1.0)	0.09	0.7 (0.6–0.9)	0.01
Mental health treatment in past year										
Inpatient	0.9 (0.6–1.2)	0.31	0.8 (0.6–1.0)	0.04	0.8 (0.6–1.0)	0.07	0.9 (0.6–1.2)	0.41	1.0 (0.6–1.5)	0.96
Outpatient	0.9 (0.8–0.9)	0.002	0.9 (0.8–1.0)	0.10	0.9 (0.8–1.1)	0.23	0.9 (0.7–1.1)	0.17	0.9 (0.7–1.2)	0.46
Medication	0.9 (0.8–1.0)	0.04	0.8 (0.7–0.9)	<0.0001	0.8 (0.7–0.9)	0.004	0.8 (0.7–1.0)	0.01	0.9 (0.7–1.2)	0.44
Needed but did not receive	1.0 (0.9–1.1)	0.47	0.9 (0.8–1.1)	0.44	0.8 (0.7–0.9)	0.001	0.8 (0.7–1.0)	0.08	1.0 (0.8–1.4)	0.93
Symptoms of mental disorders in past year										
Panic attacks	0.9 (0.9–1.1)	0.30	0.9 (0.8–1.0)	0.006	1.0 (0.9–1.2)	0.98	1.0 (0.8–1.1)	0.61	0.8 (0.6–1.0)	0.09
Major depressive episode	1.0 (0.8–1.1)	0.61	0.9 (0.8–1.1)	0.18	0.9 (0.7–1.0)	0.14	0.9 (0.7–1.2)	0.67	0.8 (0.5–1.1)	0.21
Mania	1.2 (0.9–1.8)	0.23	0.8 (0.6–1.0)	0.08	0.8 (0.6–1.2)	0.24	0.8 (0.5–1.2)	0.22	0.8 (0.5–1.3)	0.33
Social phobia	1.0 (0.6–1.5)	0.93	0.8 (0.5–1.1)	0.20	0.7 (0.5–1.0)	0.06	1.0 (0.6–1.6)	0.90	1.2 (0.6–2.4)	0.61
Generalized anxiety disorder	0.9 (0.7–1.1)	0.30	0.8 (0.7–1.1)	0.19	0.9 (0.7–1.1)	0.31	0.9 (0.7–1.3)	0.63	1.1 (0.6–1.7)	0.85
Agoraphobia	1.0 (0.6–1.7)	0.94	0.8 (0.5–1.2)	0.27	0.6 (0.4–0.9)	0.005	1.1 (0.7–1.7)	0.75	0.7 (0.3–1.4)	0.26
Posttraumatic stress disorder	1.2 (1.0–1.6)	0.08	0.9 (0.7–1.2)	0.41	0.9 (0.7–1.2)	0.36	0.9 (0.6–1.2)	0.41	1.0 (0.6–1.6)	0.92
Non-affective psychosis ^c	0.9 (0.7–1.2)	0.51	0.9 (0.6–1.2)	0.42	0.8 (0.6–1.1)	0.27	0.8 (0.6–1.1)	0.17	0.9 (0.6–1.3)	0.51
Specific psychotic symptoms in past year										
Heard voices	1.0 (0.7–1.3)	0.73	1.0 (0.8–1.3)	0.94	0.9 (0.6–1.3)	0.55	0.8 (0.6–1.3)	0.45	0.8 (0.6–1.3)	0.41
Felt force taking over mind	0.7 (0.5–1.0)	0.08	0.6 (0.5–0.9)	0.004	0.7 (0.5–1.0)	0.04	0.9 (0.5–1.4)	0.54	0.7 (0.4–1.3)	0.26
Felt force inserting thoughts	0.9 (0.6–1.5)	0.72	0.7 (0.4–1.2)	0.23	1.2 (0.7–1.8)	0.51	1.3 (0.8–2.3)	0.31	1.7 (0.8–3.5)	0.19
Felt force steal thoughts	0.9 (0.5–1.5)	0.62	0.8 (0.5–1.4)	0.48	0.8 (0.4–1.5)	0.47	0.7 (0.4–1.1)	0.08	1.3 (0.7–2.5)	0.36
Force used special signals	0.9 (0.7–1.3)	0.73	0.9 (0.7–1.3)	0.60	1.0 (0.8–1.4)	0.84	1.1 (0.8–1.5)	0.69	1.4 (1.0–1.9)	0.06
Believed plot to harm you	0.9 (0.6–1.3)	0.62	1.0 (0.6–1.5)	0.65	0.9 (0.6–1.5)	0.66	0.8 (0.4–1.4)	0.38	1.1 (0.6–1.9)	0.82
Saw vision	1.0 (0.8–1.3)	0.91	0.9 (0.7–1.3)	0.66	0.9 (0.7–1.2)	0.50	0.8 (0.5–1.0)	0.08	1.3 (0.8–2.1)	0.22

^aAdjusted for age, gender, race/ethnicity, income, education, married, risky behavior, extremely stressful event, and ten types of lifetime drug use (cannabis/marijuana, opiates, cocaine, sedatives/tranquilizers, stimulants, MDMA/ecstasy, inhaled anesthetics, amyl nitrates, other inhalants, PCP).

^bAdjusted for above variables plus nine types of past year drug use (cannabis/marijuana, opiates, cocaine, sedatives/tranquilizers, stimulants, MDMA/ecstasy, inhalants, PCP).

^cData on symptoms of non-affective psychosis available only for years 2001–2002.

Bold indicates p<0.05.

doi:10.1371/journal.pone.0063972.t004

“Flashbacks” and Perceptual Phenomena

In this study, lifetime use of psychedelics and past year use of LSD was not associated with past year symptoms of visual phenomena (“seeing something others could not”), panic attacks, psychosis, or overall serious psychological distress. Thus, our findings does not support either the idea of “flashbacks” described in extreme cases as recurrent psychotic episodes, hallucinations, or panic attacks, or the more recent “hallucinogen persisting perceptual disorder” (HPPD) described as persistent visual phenomena with accompanying anxiety and distress. All of the purported symptoms of HPPD are also present in people who have never used psychedelics [42,43]. Occasional visual phenomena are common in the general population [44,45], especially among people with anxiety disorders [46]. Recent randomized controlled trials with psilocybin do not report any cases of “flashbacks” or persistent visual phenomena [8,9,20]. Interviews with over 500 regular participants in Native American peyote ceremonies did not identify anyone with “flashbacks” or persistent visual symptoms [37]. Interviews with 120 adults in the US complaining of

persistent visual symptoms found that only 5% had ever used LSD (in comparison, over 10% of the general US adult population has used LSD [4]) and there did not seem to be any relationship between drug use and visual symptoms [47]. Only two small studies have reported higher rates of visual symptoms in LSD users compared to non-users [42,43]. Both studies had serious methodological problems: participants in both studies were psychiatric inpatients who knew that the purpose of the studies was to document harms from LSD; the LSD group and the control groups were not matched on other drug use or psychiatric diagnosis; and in the first study several of the people included in the LSD group were later found to have epilepsy, panic, anxiety, affective disorder, or temporoparietal abnormalities that may be related to visual symptoms [48]. In case reports of “flashbacks” or HPPD, symptom onset is often weeks, even years, after last psychedelic use, and a causal relationship between persistent perceptual symptoms and use of psychedelics remains unproven. Overall, the validity of the HPPD diagnosis remains scant. HPPD appears to fit within the somatic symptom disorders [49]. In an

illustrative case example, a young man was diagnosed with HPPD by the originator of the diagnosis; symptoms began in conjunction with major life changes and several weeks after taking LSD; on initial consultation with physicians, he was told that his vision was fine and somatization disorder was implied; he improved after psychotherapy for his depression and worries, and reassurance that his visual experiences were ordinary perceptual phenomena that most people ignore [50].

Comments on Case Reports

Case reports of long-term psychiatric problems attributed to LSD, include psychosis, panic attacks, other anxiety disorders, and depression [3,51]. There are very few case reports of prolonged psychiatric symptoms following psilocybin or mescaline [13,52]. Almost all claims of psychiatric harm caused by peyote have been found on examination of medical records to be due to pre-existing schizophrenia or other causes [53,54]. Several issues are important to keep in mind when considering case reports [13,51]. 1) Adverse effects of psychedelics are usually short-lived; serious psychiatric symptoms following psychedelic are typically resolved within 24 hours or at least within a few days. 2) Both mental illness and psychedelic use are prevalent in the population, likely leading to many chance associations; for instance, about 3% of the general public will have a psychotic disorder sometime in their lives [55]. 3) The typical onset period of both mental illness and psychedelic use occurs in late adolescence and early adulthood, again possibly leading to mistaken causal inferences. 4) Most case reports do not rule-out preexisting psychiatric difficulties, life stresses, or use of other drugs. Many psychiatric disorders are believed to be heavily

influenced by genetics and earlier experiences, even if symptoms are often first triggered by a stressful event. Note, however, that people with first-episode psychosis often have no apparent family or personal history of mental illness, whether or not if they have previously used psychedelics [41]. 5) Because of the striking subjective effects of psychedelics, some people attribute psychiatric symptoms to the use of psychedelics even if the symptoms started months or years later. 6) Some health professionals may have a biased view since they meet people with mental health problems and have little or no contact with the majority of psychedelic users. 7) Caution should be used when generalizing from LSD to other psychedelics because of emerging evidence of unique effects of LSD [56]. 8) Case reports of mental health problems following psychedelics are often comparable to case reports of mental health problems linked to intensive meditation [57–61], visiting holy sites [62,63], or viewing beautiful artwork and sublime natural scenes [64].

Acknowledgments

The Substance Abuse and Mental Health Data Archive provided the data files from the National Survey on Drug Use and Health, which was sponsored by the Office of Applied Studies of the Substance Abuse and Mental Health Services Administration.

Author Contributions

Conceived and designed the experiments: TSK PÖJ. Analyzed the data: TSK. Wrote the paper: PÖJ TSK.

References

- McGlothlin WH (1964) Hallucinogenic Drugs: A Perspective with Special Reference to Peyote and Cannabis. RAND Corp. Available: <http://www.rand.org/pubs/papers/P2937.html>. Accessed 2013 Apr 30.
- Bruhn JG, De Smet PA, El-Seedi HR, Beck O (2002) Mescaline use for 5700 years. *Lancet* 359: 1866.
- Nichols DE (2004) Hallucinogens. *Pharmacol Ther* 101: 131–181.
- Krebs TS, Johansen PO (2013) Over 30 million psychedelic users in the United States. F1000 Research (in press).
- Hallock RM, Dean A, Knecht ZA, Spencer J, Taverna EC (2012) A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. *Drug Alcohol Depend*. 2012 Dec 19 [Epub ahead of print]. pii: S0376-8716(12)00451-6. doi:10.1016/j.drugalcdep.2012.11.010.
- Briggs G, Freeman RK, Sumner JY (2011) *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk*. 9th ed. Lippincott Williams & Wilkins.
- McGlothlin WH, Arnold DO (1971) LSD revisited. A ten-year follow-up of medical LSD use. *Arch Gen Psychiatry* 24: 35–49.
- Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol* 22: 621–632.
- Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology (Berl)* 218: 649–665.
- Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV (2010) Harms associated with psychoactive substances: findings of the UK National Drug Survey. *J Psychopharmacol* 24: 147–153.
- Carhart-Harris RL, Nutt DJ (2010) User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. *J Subst Abuse* 15: 283–300.
- Doblin R (1991) Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique. *J Transpersonal Psy* 23: 1–25.
- McWilliams SA, Tuttle RJ (1973) Long-term psychological effects of LSD. *Psychol Bull* 79: 341–351.
- Hoaken PNS, Stewart SH (2003) Drugs of abuse and the elicitation of human aggressive behavior. *Addict Behav* 28: 1533–1554.
- European Monitoring Centre for Drugs and Drug Addiction (2011) *Drug Profiles: Lysergide (LSD)*. Available: <http://www.emcdda.europa.eu/publications/drug-profiles/lsd>. Accessed 2013 Apr 30.
- Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. *Lancet* 369: 1047–1053.
- Nutt DJ, King LA, Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. *Lancet* 376: 1558–65.
- Van Amsterdam J, Opperhuizen A, Koeter M, Van den Brink W (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. *Eur Addict Res* 16: 202–207.
- Taylor M, Mackay K, Murphy J, McIntosh A, McIntosh C, et al. (2012) Quantifying the RR of harm to self and others from substance misuse: results from a survey of clinical experts across Scotland. *BMJ Open* 2: e000774.
- Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *J Psychopharmacol* 25: 1434–1452.
- González-Maeso J, Weisstaub N, Zhou M, Chan P, Ivic L, et al. (2007) Hallucinogens recruit specific cortical 5-HT_{2A} receptor-mediated signaling pathways to affect behavior. *Neuron* 53: 439–452.
- American Psychiatric Association (1994) *Diagnostic and statistical manual of mental health disorders*. 4th ed. Washington DC: American Psychiatric Association.
- Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, et al. (2003) Screening for serious mental illness in the general population. *Arch Gen Psychiatry* 60: 184–189.
- Sunderland M, Andrews G, Slade T, Peters L (2011) Measuring the level of diagnostic concordance and discordance between modules of the CIDI-Short Form and the CIDI-Auto 2.1. *Soc Psychiatry Psychiatr Epidemiol* 46: 775–785.
- International Consortium in Psychiatric Epidemiology (2005) Appendix for "New Scales to Screen for Serious Mental Illness in the General Population". Available: http://www.hcp.med.harvard.edu/icpe/smi_appendix.php. Accessed 2013 Apr 30.
- Patel V, Lund C, Hatherill S, Plagerson S, Corrigan J, et al. (2010) Mental disorders: equity and social determinants. In: Blas E, Sivasankara Kurup A, editors. *Equity, social determinants and public health programmes*. World Health Organization. pp.115–134.
- Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 165: 710–718.
- Catts VS, Catts SV (2010) Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia? In: Sachdev PS, Keshavan MS, editors. *Secondary Schizophrenia*. Cambridge University Press. pp.141–168.
- Van Amsterdam J, Opperhuizen A, Van den Brink W (2011) Harm potential of magic mushroom use: a review. *Regul Toxicol Pharmacol* 59: 423–429.
- European Monitoring Centre for Drugs and Drug Addiction (2011) *Drug Profiles: Hallucinogenic Mushrooms*. Available: <http://www.emcdda.europa.eu/publications/drug-profiles/mushrooms>. Accessed 2013 Apr 30.

31. National Institute on Drug Abuse (2009) DrugFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP. Available: <http://www.drugabuse.gov/publications/drugfacts/hallucinogens-ld-psyote-psilocybin-pcp>. Accessed 2013 Apr 30.
32. United Nations Office on Drugs and Crime (2012) Get the Facts: Hallucinogens. Available: <http://www.unodc.org/drugs/en/get-the-facts/hallucinogens.html>. Accessed 2013 Apr 30.
33. Department of Health and the Home Office (2012) LSD. FRANK Drug Awareness Campaign. Available: <http://www.talktofrank.com/drug/LSD>. Accessed 2013 Apr 30.
34. Department of Health and the Home Office (2012) Magic Mushrooms. FRANK Drug Awareness Campaign. Available: <http://www.talktofrank.com/drug/magic-mushrooms>. Accessed 2013 Apr 30.
35. Johnston LD, O'Malley PM (1997) The recanting of earlier reported drug use by young adults. *NIDA Res Monogr* 167: 59–80.
36. Laing R, Siegel JA, editors (2003) *Hallucinogens: A Forensic Drug Handbook*. Academic Press.
37. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. *Biol Psychiatry* 58: 624–631.
38. Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, et al. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. *PLoS One* 7: e42421.
39. Kuzenko N, Sareen J, Beesdo-Baum K, Perkonig A, Höfler M, et al. (2011) Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample. *Acta Psychiatr Scand* 123: 466–474.
40. Bonn-Miller MO, Bernstein A, Sachs-Ericsson N, Schmidt NB, Zvolensky MJ (2007) Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. *J Anxiety Disord* 21: 730–741.
41. Vardy MM, Kay SR (1983) LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. *Arch Gen Psychiatry* 40: 877–883.
42. Abraham HD (1983) Visual phenomenology of the LSD flashback. *Arch Gen Psychiatry* 40: 884–889.
43. Batzer W, Ditzler T, Brown C (1999) LSD use and flashbacks in alcoholic patients. *J Addict Dis* 18: 57–63.
44. Pechey R, Halligan P (2012) Prevalence and correlates of anomalous experiences in a large non-clinical sample. *Psychol Psychother* 85: 150–162.
45. Caputo GB (2010) Apparitional experiences of new faces and dissociation of self-identity during mirror gazing. *Percept Mot Skills* 110: 1125–1138.
46. Ohayon MM (2000) Prevalence of hallucinations and their pathological associations in the general population. *Psychiatry Res* 97: 153–164.
47. Schankin CJ, Maniyar F, Goadsby PJ (2012) Field-testing the criteria for “visual snow” (positive persistent visual disturbance). F1000 Posters 3. Available: <http://f1000.com/posters/browse/summary/1090714>. Accessed 2013 Apr 30.
48. Halpern JH, Pope Jr HG (2003) Hallucinogen persisting perception disorder: What do we know after 50 years? *Drug Alcohol Depend* 69: 109–119.
49. Voigt K, Wollburg E, Weinmann N, Herzog A, Meyer B, et al. (2012) Predictive validity and clinical utility of DSM-5 Somatic Symptom Disorder - Comparison with DSM-IV somatoform disorders and additional criteria for consideration. *J Psychosomatic Res* 73: 345–350.
50. Genova P (2002) *The Permanent Trip. The Thaw: Reclaiming the Person for Psychiatry*. Hillsdale, NJ: Analytic Press. pp.17–19.
51. Henderson LA (1998) Adverse reaction to LSD. LSD: Still with us after all these years. San Francisco, CA: Jossey-Bass. pp.55–75.
52. Andersson C, Kristinsson J, Gry J (2009) Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids. Nordic Council of Ministers. Available: <http://www.norden.org/en/publications/publikationer/2008-606/>. Accessed 2013 Apr 30.
53. Aberle DF (1991) *The Peyote Religion Among the Navaho*. 2nd ed. University of Oklahoma Press.
54. Bergman RL (1971) Navajo peyote use: its apparent safety. *Am J Psychiatry* 128: 695–699.
55. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry* 64: 19–28.
56. Marona-Lewicka D, Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. *Pharmacol Biochem Behav* 87: 453–461.
57. Garden M (2007) Can meditation be bad for you? *The Humanist*. Available: <http://www.thehumanist.org/humanist/MaryGarden.html>. Accessed 2013 Apr 30.
58. Shapiro DH Jr (1992) Adverse effects of meditation: a preliminary investigation of long-term meditators. *Int J Psychosom* 39: 62–7.
59. Kuijpers HJH, Van der Heijden FMMA, Tuinier S, Verhoeven WMA (2007) Meditation-induced psychosis. *Psychopathology* 40: 461–464.
60. Lyons D (2001) Soviet-style psychiatry is alive and well in the People's Republic. *Br J Psychiatry* 178: 380–381.
61. Lee S (2001) Who is politicising psychiatry in China? *Br J Psychiatry* 179: 178–179.
62. Bar-el Y, Durst R, Katz G, Zislin J, Strauss Z, et al. (2000) Jerusalem syndrome. *Br J Psychiatry* 176: 86–90.
63. Kalian M, Witztum E (2000) Comments on Jerusalem syndrome. *Br J Psychiatry* 176: 492.
64. Nicholson TRJ, Pariante C, McLoughlin D (2009) Stendhal syndrome: a case of cultural overload. *BMJ Case Reports* 2009: pii: bcr06.2008.0317.